Sanara MedTech Inc. sold all of the assets of Tissue Health Plus, LLC, a wholly owned subsidiary of the Company, including THP’s business software products…
Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. On October 6, 2026, Sanara MedTech Inc. (the “Company”) sold all of the assets of Tissue Health Plus, LLC, a wholly owned subsidiary of the Company (“THP”), including THP’s business software products and related intellectual property, to an unr
- Counterparty
- an unrelated third party
- Seller
- Sanara MedTech Inc.
- Deal value
- approximately $2,000,000
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The modest cash inflow is offset by the loss of a software business line, likely resulting in a neutral to slightly negative reaction in the stock.
Market read
A small‑scale asset divestiture with limited market impact; primarily relevant to investors holding SMTI.
What to watch
Potential earnout rights may provide future upside if the buyer meets performance targets.
Background
Sanara MedTech filed an 8‑K reporting the sale of its wholly‑owned subsidiary Tissue Health Plus, including software products and IP, for approximately $2 million.
Ticker impact
Sanara MedTech disclosed the sale of its subsidiary Tissue Health Plus for $2 million, a new material transaction for the company.
slight downside as investors price the loss of THP's software revenue
The transaction size is small relative to the company's market cap, so the market impact will be limited but negative.
Market effects
Minimal effect on the broader med‑tech software sector; the divestiture is company‑specific.
Limited to Sanara MedTech's share price; no broader regional impact.
None
Counterpoint
The cash from the sale could be redeployed into higher‑growth initiatives, offering upside potential.
Key entities
- companySanara MedTech Inc.
Issuer of the 8‑K filing and seller of the subsidiary.
- subsidiaryTissue Health Plus, LLC
Wholly‑owned subsidiary whose assets were sold.


